In This Issue
Cancer Discov September 1 2016 6 (9) 932-935; DOI:10.1158/2159-8290.CD-ITI6-9
MET amplification promotes resistance to dual EGFR and BRAF inhibition, and a patient with resistant metastatic colorectal cancer showed an early response to ongoing treatment with MET and BRAF inhibitors.
Stimulation of T cell–receptor signaling using anti-CD3 antibody reactivates a lineage-specific negative selection checkpoint and induces tumor cell death in T-ALL.
Epigenetic upregulation of IL15 induces cutaneous T-cell lymphoma by enhancing expression of HDAC1 and HDAC6, suggesting the potential for treatment with specifi c HDAC inhibitors.
EZH2 overexpression drives a subset of NSCLCs that are molecularly distinct from KRAS-mutant and EGFR-mutant tumors and may be vulnerable to EZH2 inhibition.
Endogenous complement inhibits IL10 production by CD8+ tumor infiltrating lymphocytes to decrease antitumor immunity and drive tumorigenesis.
miR-3662 contributes to the hematopoietic differentiation phenotypes associated with the master hematopoietic regulatory quantitative trait locus in chromosome 6q23.3.
Meta-analyses of multiple GWAS studies identified seven pleiotropic susceptibility loci in three hormone-related cancers.